Effect of race/ethnicity on participation in HIV vaccine trials and comparison to other trials of biomedical prevention

References

• An Q, Prejean J, Hall HI. Racial disparity in U.S. diagnoses of acquired immune deficiency syndrome, 2000-2009. Am J Prev Med 2012; 43:461 - 6; http://dx.doi.org/10.1016/j.amepre.2012.07.040; PMID: 23079167
   PubMed Web of Science ®Google Scholar
• Kraut-Becher J, Eisenberg M, Voytek C, Brown T, Metzger DS, Aral S. Examining racial disparities in HIV: lessons from sexually transmitted infections research. J Acquir Immune Defic Syndr 2008; 47:S20 - 7; http://dx.doi.org/10.1097/QAI.0b013e3181605b95; PMID: 18301130
   PubMed Web of Science ®Google Scholar
• Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, et al, HVTN 505 Study Team. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 2013; 369:2083 - 92; http://dx.doi.org/10.1056/NEJMoa1310566; PMID: 24099601
   PubMed Web of Science ®Google Scholar
• Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, et al, Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881 - 93; http://dx.doi.org/10.1016/S0140-6736(08)61591-3; PMID: 19012954
   PubMed Web of Science ®Google Scholar
• Colfax G, Buchbinder S, Vamshidar G, Celum C, McKirnan D, Neidig J, Koblin B, Gurwith M, Bartholow B. Motivations for participating in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 2005; 39:359 - 64; http://dx.doi.org/10.1097/01.qai.0000152039.88422.ec; PMID: 15980699
   PubMed Web of Science ®Google Scholar
• Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF, rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654 - 65; http://dx.doi.org/10.1086/428404; PMID: 15688278
   PubMed Web of Science ®Google Scholar
• Djomand G, Katzman J, di Tommaso D, Hudgens MG, Counts GW, Koblin BA, Sullivan PS. Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002. Public Health Rep 2005; 120:543 - 8; PMID: 16224987
   PubMed Web of Science ®Google Scholar
• Newman PA, Logie C. HIV vaccine acceptability: a systematic review and meta-analysis. AIDS 2010; 24:1749 - 56; http://dx.doi.org/10.1097/QAD.0b013e32833adbe8; PMID: 20597165
   PubMed Web of Science ®Google Scholar
• Hurley-Rosenblatt A, Dorsen C. Barriers to volunteer enrollment in HIV preventive vaccine clinical research trials: a review of the literature. J Assoc Nurses AIDS Care 2011; 22:330 - 4; http://dx.doi.org/10.1016/j.jana.2010.12.001; PMID: 21256768
   PubMed Web of Science ®Google Scholar
• Dhalla S, Poole G. Motivators of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies. AIDS Care 2011; 23:1430 - 47; http://dx.doi.org/10.1080/09540121.2011.555750; PMID: 21722022
   PubMed Web of Science ®Google Scholar
• Dhalla S, Poole G. Barriers of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies. Vaccine 2011; 29:5850 - 9; http://dx.doi.org/10.1016/j.vaccine.2011.06.055; PMID: 21740947
   PubMed Web of Science ®Google Scholar
• Mills E, Cooper C, Guyatt G, Gilchrist A, Rachlis B, Sulway C, Wilson K. Barriers to participating in an HIV vaccine trial: a systematic review. AIDS 2004; 18:2235 - 42; http://dx.doi.org/10.1097/00002030-200411190-00003; PMID: 15577535
   PubMed Web of Science ®Google Scholar
• Newman PA, Duan N, Rudy ET, Anton PA. Challenges for HIV vaccine dissemination and clinical trial recruitment: if we build it, will they come?. AIDS Patient Care STDS 2004; 18:691 - 701; http://dx.doi.org/10.1089/apc.2004.18.691; PMID: 15659880
   PubMed Web of Science ®Google Scholar
• Tello J, Soong SJ, Hunter B, Meriwether R, Hook EW 3rd, Mulligan MJ. HIV vaccine acceptance among heterosexual clients of a sexually transmitted diseases clinic. Am J Med Sci 1998; 315:11 - 6; http://dx.doi.org/10.1097/00000441-199801000-00003; PMID: 9427569
   PubMed Web of Science ®Google Scholar
• Strauss RP, Sengupta S, Kegeles S, McLellan E, Metzger D, Eyre S, Khanani F, Emrick CB, MacQueen KM. Willingness to volunteer in future preventive HIV vaccine trials: issues and perspectives from three U.S. communities. J Acquir Immune Defic Syndr 2001; 26:63 - 71; http://dx.doi.org/10.1097/00126334-200101010-00010; PMID: 11176270
   PubMed Web of Science ®Google Scholar
• Brooks RA, Newman PA, Duan N, Ortiz DJ. HIV vaccine trial preparedness among Spanish-speaking Latinos in the US. AIDS Care 2007; 19:52 - 8; http://dx.doi.org/10.1080/09540120600872711; PMID: 17129857
   PubMed Web of Science ®Google Scholar
• Moutsiakis DL, Chin PN. Why blacks do not take part in HIV vaccine trials. J Natl Med Assoc 2007; 99:254 - 7; PMID: 17393949
   PubMed Web of Science ®Google Scholar
• Allen MA, Liang TS, La Salvia T, Tjugum B, Gulakowski RJ, Murguía M. Assessing the attitudes, knowledge, and awareness of HIV vaccine research among adults in the United States. J Acquir Immune Defic Syndr 2005; 40:617 - 24; http://dx.doi.org/10.1097/01.qai.0000174655.63653.38; PMID: 16284540
   PubMed Web of Science ®Google Scholar
• Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlwe S, Cowan F, Casapia M, Ortiz A, Fuchs J, et al, HPTN 039 Protocol Team. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:2109 - 19; http://dx.doi.org/10.1016/S0140-6736(08)60920-4; PMID: 18572080
   PubMed Web of Science ®Google Scholar
• Hosek SG, Siberry G, Bell M, Lally M, Kapogiannis B, Green K, Fernandez MI, Rutledge B, Martinez J, Garofalo R, et al, Adolescent Trials Network for HIVAIDS Interventions (ATN). The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men. J Acquir Immune Defic Syndr 2013; 62:447 - 56; http://dx.doi.org/10.1097/QAI.0b013e3182801081; PMID: 24135734
   PubMed Web of Science ®Google Scholar
• Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, et al, iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587 - 99; http://dx.doi.org/10.1056/NEJMoa1011205; PMID: 21091279
   PubMed Web of Science ®Google Scholar
• Grohskopf LA, Chillag KL, Gvetadze R, Liu AY, Thompson M, Mayer KH, Collins BM, Pathak SR, Oʼhara B, Ackers ML, et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr 2013; 64:79 - 86; http://dx.doi.org/10.1097/QAI.0b013e31828ece33; PMID: 23466649
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al, HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301 - 14; http://dx.doi.org/10.1016/S0140-6736(09)61248-4; PMID: 19586656
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, et al, HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161 - 70; http://dx.doi.org/10.1016/S0140-6736(07)60946-5; PMID: 17602732
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration Package Insert (Cervarix) @ http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM186981.pdf. Accessed February 26, 2014.
   Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, et al, Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928 - 43; http://dx.doi.org/10.1056/NEJMoa061760; PMID: 17494926
   PubMed Web of Science ®Google Scholar
• FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915 - 27; http://dx.doi.org/10.1056/NEJMoa061741; PMID: 17494925
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr., Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011; 364:401 - 11; http://dx.doi.org/10.1056/NEJMoa0909537; PMID: 21288094
   PubMed Web of Science ®Google Scholar
• Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr., Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365:1576 - 85; http://dx.doi.org/10.1056/NEJMoa1010971; PMID: 22029979
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration Package Insert (Gardasil) @ http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111263.pdf. Accessed February 26, 2014.
   Google Scholar
• Sengupta S, Strauss RP, DeVellis R, Quinn SC, DeVellis B, Ware WB. Factors affecting African-American participation in AIDS research. J Acquir Immune Defic Syndr 2000; 24:275 - 84; http://dx.doi.org/10.1097/00126334-200007010-00014; PMID: 10969353
   PubMed Web of Science ®Google Scholar
• Seage GR 3rd, Holte SE, Metzger D, Koblin BA, Gross M, Celum C, Marmor M, Woody G, Mayer KH, Stevens C, et al. Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol 2001; 153:619 - 27; http://dx.doi.org/10.1093/aje/153.7.619; PMID: 11282787
   PubMed Web of Science ®Google Scholar
• Bartholow BN, MacQueen KM, Douglas JM Jr., Buchbinder S, McKirnan D, Judson FN. Assessment of the changing willingness to participate in phase III HIV vaccine trials among men who have sex with men. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:108 - 15; http://dx.doi.org/10.1097/00042560-199710010-00006; PMID: 9358105
   PubMedGoogle Scholar
• Koblin BA, Heagerty P, Sheon A, Buchbinder S, Celum C, Douglas JM, Gross M, Marmor M, Mayer K, Metzger D, et al. Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States. AIDS 1998; 12:785 - 93; http://dx.doi.org/10.1097/00002030-199807000-00015; PMID: 9619811
   PubMed Web of Science ®Google Scholar
• Frew PM, Archibald M, Martinez N, del Rio C, Mulligan MJ. Promoting HIV vaccine research in African American communities: does the Theory of Reasoned Action explain potential outcomes of involvement?. Challenge (Atlanta Ga) 2007; 13:61 - 97; PMID: 20686675
   PubMedGoogle Scholar
• Golub ET, Purvis LA, Sapun M, Safaeian M, Beyrer C, Vlahov D, Strathdee SA. Changes in willingness to participate in HIV vaccine trials among HIV-negative injection drug users. AIDS Behav 2005; 9:301 - 9; http://dx.doi.org/10.1007/s10461-005-9004-3; PMID: 16088366
   PubMed Web of Science ®Google Scholar
• Metch B, Frank I, Novak R, Swann E, Metzger D, Morgan C, Lucy D, Dunbar D, Graham P, Madenwald T, et al. Recruitment of urban US women at risk for HIV infection and willingness to participate in future HIV vaccine trials. AIDS Behav 2013; 17:760 - 72; http://dx.doi.org/10.1007/s10461-012-0351-6; PMID: 23090677
   PubMed Web of Science ®Google Scholar
• Strathdee SA, Hogg RS, Cornelisse PG, Martindale SL, Currie SL, O’Shaugnessy MV, Schechter MT. Factors associated with willingness to participate in HIV vaccine trials among HIV-negative injection drug users and young gay and bisexual men. AIDS Behav 2000; 4:271 - 8; http://dx.doi.org/10.1023/A:1009520802874
   Google Scholar
• Meyers K, Metzger DS, McLellan AT, Navaline H, Sheon AR, Woody GE. Will preventive HIV vaccine efficacy trials be possible with female injection drug users?. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:577 - 85; http://dx.doi.org/10.1097/00042560-199510050-00012; PMID: 8548338
   PubMedGoogle Scholar
• Meyers K, Metzger DS, Navaline H, Woody GE, McLellan AT. HIV vaccine trials: will intravenous drug users enroll?. Am J Public Health 1994; 84:761 - 6; http://dx.doi.org/10.2105/AJPH.84.5.761; PMID: 8179045
   PubMed Web of Science ®Google Scholar
• Hays RB, Kegeles SM. Factors related to the willingness of young gay men to participate in preventive HIV vaccine trials. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:164 - 71; http://dx.doi.org/10.1097/00042560-199902010-00009; PMID: 10048904
   PubMedGoogle Scholar
• Koblin BA, Avrett S, Taylor PE, Stevens CE. Willingness to participate in HIV-1 vaccine efficacy trials and the effect of media events among gay and bisexual men in New York City: Project ACHIEVE. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15:165 - 71; http://dx.doi.org/10.1097/00042560-199706010-00011; PMID: 9241117
   PubMedGoogle Scholar
• Gross M, Seage GR, Mayer KH, Goldstein RS, Losina E, Wold C. Interest among gay/bisexual men in greater Boston in participating in clinical trials of preventive HIV vaccines. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12:406 - 12; http://dx.doi.org/10.1097/00042560-199608010-00012; PMID: 8673551
   PubMedGoogle Scholar
• Koblin BA, Holte S, Lenderking B, Heagerty P, The HIVNET Vaccine Preparedness Study Protocol Team. Readiness for HIV vaccine trials: changes in willingness and knowledge among high-risk populations in the HIV network for prevention trials. J Acquir Immune Defic Syndr 2000; 24:451 - 7; http://dx.doi.org/10.1097/00126334-200008150-00010; PMID: 11035616
   PubMed Web of Science ®Google Scholar
• Brown-Peterside P, Rivera E, Lucy D, Slaughter I, Ren L, Chiasson MA, Koblin BA. Retaining hard-to-reach women in HIV prevention and vaccine trials: Project ACHIEVE. Am J Public Health 2001; 91:1377 - 9; http://dx.doi.org/10.2105/AJPH.91.9.1377; PMID: 11527761
   PubMed Web of Science ®Google Scholar
• Brown-Peterside P, Chiasson MA, Ren L, Koblin BA. Involving women in HIV vaccine efficacy trials: lessons learned from a vaccine preparedness study in New York City. J Urban Health 2000; 77:425 - 37; http://dx.doi.org/10.1007/BF02386751; PMID: 10976615
   PubMed Web of Science ®Google Scholar
• Buchbinder SP, Douglas JM Jr., McKirnan DJ, Judson FN, Katz MH, MacQueen KM. Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: risk behavior, seroincidence, and willingness to participate. J Infect Dis 1996; 174:954 - 61; http://dx.doi.org/10.1093/infdis/174.5.954; PMID: 8896495
   PubMed Web of Science ®Google Scholar
• Koblin BA, Taylor PE, Avrett S, Stevens CE. The feasibility of HIV-1 vaccine efficacy trials among gay/bisexual men in New York City: Project ACHIEVE. AIDS Community Health Initiative Enroute to the Vaccine EFfort. AIDS 1996; 10:1555 - 61; http://dx.doi.org/10.1097/00002030-199611000-00015; PMID: 8931792
   PubMed Web of Science ®Google Scholar
• Halpern SD, Metzger DS, Berlin JA, Ubel PA. Who will enroll? Predicting participation in a phase II AIDS vaccine trial. J Acquir Immune Defic Syndr 2001; 27:281 - 8; http://dx.doi.org/10.1097/00126334-200107010-00011; PMID: 11464149
   PubMed Web of Science ®Google Scholar
• Koblin BA, Metch B, Novak RM, Morgan C, Lucy D, Dunbar D, Graham P, Swann E, Madenwald T, Escamilia G, et al, HVTN 906 Study Team. Feasibility of identifying a cohort of US women at high risk for HIV infection for HIV vaccine efficacy trials: longitudinal results of HVTN 906. J Acquir Immune Defic Syndr 2013; 63:239 - 44; http://dx.doi.org/10.1097/QAI.0b013e31828ded1a; PMID: 23446497
   PubMed Web of Science ®Google Scholar
• National Institute of Allergy and Infectious Diseases. QUESTIONS AND ANSWERS: HVTN 502 and HVTN 503 HIV Vaccine Clinical Trials @http://www.niaid.nih.gov/news/qa/pages/step_qa.aspx
   Google Scholar
• Harro CD, Judson FN, Gorse GJ, Mayer KH, Kostman JR, Brown SJ, Koblin B, Marmor M, Bartholow BN, Popovic V, VAX004 Study Group. Recruitment and baseline epidemiologic profile of participants in the first phase 3 HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 2004; 37:1385 - 92; http://dx.doi.org/10.1097/01.qai.0000122983.87519.b5; PMID: 15483468
   PubMed Web of Science ®Google Scholar
• HIV vaccine trials network. Data from STEP Study Presented at Open Scientific Session Confirm Merck's Investigational HIV Vaccine was not Effective http://www.hvtn.org/media/pr/step.html. Accessed February 26, 2014.
   Google Scholar
• Koblin BA, Mayer KH, Noonan E, Wang CY, Marmor M, Sanchez J, Brown SJ, Robertson MN, Buchbinder SP. Sexual risk behaviors, circumcision status, and preexisting immunity to adenovirus type 5 among men who have sex with men participating in a randomized HIV-1 vaccine efficacy trial: step study. J Acquir Immune Defic Syndr 2012; 60:405 - 13; http://dx.doi.org/10.1097/QAI.0b013e31825325aa; PMID: 22421748
   PubMed Web of Science ®Google Scholar
• VaxGen trial social and behavioral data VAX report 2003; 1(1) Available from: http://www.vaxreport.org/Back-Issues/Pages/VaxGentrialsocialandbehavioraldata.aspx. Accessed April 1, 2014.
   Google Scholar
• Newman PA, Duan N, Kakinami L, Roberts K. What can HIV vaccine trials teach us about future HIV vaccine dissemination?. Vaccine 2008; 26:2528 - 36; http://dx.doi.org/10.1016/j.vaccine.2008.03.004; PMID: 18420313
   PubMed Web of Science ®Google Scholar
• Newman PA, Duan N, Roberts KJ, Seiden D, Rudy ET, Swendeman D, Popova S. HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment. J Acquir Immune Defic Syndr 2006; 41:210 - 7; http://dx.doi.org/10.1097/01.qai.0000179454.93443.60; PMID: 16394854
   PubMed Web of Science ®Google Scholar
• Francis DP, Heyward WL, Popovic V, Orozco-Cronin P, Orelind K, Gee C, Hirsch A, Ippolito T, Luck A, Longhi M, et al. Candidate HIV/AIDS vaccines: lessons learned from the World’s first phase III efficacy trials. AIDS 2003; 17:147 - 56; http://dx.doi.org/10.1097/00002030-200301240-00003; PMID: 12545073
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. NIH Policy and Guidelines on The Inclusion of Women and Minorities as Subjects in Clinical Research – Amended, October, 2001 http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm. Accessed February 26, 2014
   Google Scholar
• Rida W, Fast P, Hoff R, Fleming T. Intermediate-size trials for the evaluation of HIV vaccine candidates: a workshop summary. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:195 - 203; http://dx.doi.org/10.1097/00042560-199711010-00009; PMID: 9390572
   PubMedGoogle Scholar
• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al, MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209 - 20; http://dx.doi.org/10.1056/NEJMoa0908492; PMID: 19843557
   PubMed Web of Science ®Google Scholar
• Koblin BA, Mayer KH, Eshleman SH, Wang L, Mannheimer S, del Rio C, Shoptaw S, Magnus M, Buchbinder S, Wilton L, et al, HPTN 061 Protocol Team. Correlates of HIV acquisition in a cohort of Black men who have sex with men in the United States: HIV prevention trials network (HPTN) 061. PLoS One 2013; 8:e70413; http://dx.doi.org/10.1371/journal.pone.0070413; PMID: 23922989
   PubMed Web of Science ®Google Scholar
• Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798 - 801; http://dx.doi.org/10.1038/nature08463; PMID: 19759533
   PubMed Web of Science ®Google Scholar
• McDaid LM, Hart GJ. Willingness to participate in future HIV prevention studies among gay and bisexual men in Scotland, UK: a challenge for intervention trials. AIDS Behav 2012; 16:1420 - 9; http://dx.doi.org/10.1007/s10461-011-0044-6; PMID: 22101849
   PubMed Web of Science ®Google Scholar
• Dhalla S, Woods R, Strathdee SA, Patrick DM, Hogg RS. HIV vaccine preparedness studies in the organization for economic co-operation and development (OECD) countries. AIDS Care 2007; 19:1118 - 27; http://dx.doi.org/10.1080/09540120701352258; PMID: 17851989
   PubMed Web of Science ®Google Scholar
• O’Connell JM, Hogg RS, Chan K, Strathdee SA, McLean N, Martindale SL, Willoughby B, Remis R. Willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial. J Acquir Immune Defic Syndr 2002; 31:521 - 8; http://dx.doi.org/10.1097/00126334-200212150-00010; PMID: 12473841
   PubMed Web of Science ®Google Scholar
• Vlahov D, Astemborski J, Solomon L, Galai N, Basarab L, Nelson KE. Interest in HIV vaccines among injection drug users in Baltimore, Maryland. AIDS Res Hum Retroviruses 1994; 10:Suppl 2 S265 - 8; PMID: 7865315
   PubMedGoogle Scholar